Merrimack is evidently surprised that MM-093 has shown essentially no side effects. In dose-finding studies, it’s a heck of a lot better to start too low than to start too high and run into a clinical hold.
If Merrimack manages to find a dose that is both safe and effective, MM-093 has blockbuster potential (IMO) as a second-line treatment for RA following failure on one of the TNF-a drugs. Regards, Dew
Market Data 
Markets 
AI
